ArticleHaematologica2026
The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.
Article in Haematologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Inconsistent definitions of transplant ineligibility in multiple myeloma: A systematic review.British journal of haematology · 2026Pooled it
- Article
- Nuanced treatment decision in newly diagnosed multiple myeloma patients aged 65-75 years: a real-world study.Blood research · 2026Article
- Plasma expression of long non-coding RNAFrontiers in oncology · 2026Article
Corrections and comments
- Erratum issued
Authors and funding
47 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the availability of novel agents, autologous hematopoietic cell transplantation (auto-HCT) remains the standard of care in newly diagnosed multiple myeloma (MM) patients. The impact of age on overall survival (OS), progression-free survival (PFS), relapse incidence, non-relapse mortality (NRM), and excess mortality (taking account of general population mortality) was investigated using information on 61,797 MM patients transplanted between 2013 and 2017. The median age at auto-HCT was 60.8 (range, 18.1-83.2) years of whom 2.0% were 18-39 years, 68.9% 40-64 years, 21.8% 65-69 years, 6.5% 70-74 years, and 0.8% ≥75 years of age, respectively. The corresponding OS probabilities at 3 years were 85.9%, 82.8%, 81.1%, 78.4%, and 74.8%, respectively (P<0.001). Excess mortality cumulative incidences were 13.1%, 15.0%, 14.6%, 15.0%, and 14.1% at 3 years, respectively (P=0.67). In multivariable analyses, older age was a significant risk factor for OS, PFS, and NRM but not for excess mortality or relapse risk. Our results indicate that advanced age alone should not preclude the use of auto- HCT in patients with MM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.